With box warnings

Without box warnings

Branded

Generic

3 results

mekinist
(trametinib)
Novartis Pharmaceuticals Corporation
Usage: MEKINIST is indicated for treating unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), locally advanced or metastatic anaplastic thyroid cancer, unresectable or metastatic solid tumors, and low-grade glioma with BRAF V600E/K mutations, in combination with dabrafenib, as per FDA-approved tests.
retevmo
(selpercatinib)
Eli Lilly and Company
Usage: RETEVMO is indicated for adult and pediatric patients aged 2 years and older with RET fusion-positive non-small cell lung cancer, RET-mutant advanced medullary thyroid cancer, RET fusion-positive advanced thyroid cancer, and RET fusion-positive solid tumors that require systemic therapy, following specific testing.
vitrakvi
(LAROTRECTINIB)
Bayer HealthCare Pharmaceuticals Inc.
Usage: VITRAKVI is indicated for treating adult and pediatric patients with solid tumors that have an NTRK gene fusion, are metastatic or not amenable to surgery, and lack satisfactory alternative treatments or have progressed after prior therapy, as determined by an FDA-approved test.

Medications for Solid Neoplasm

mekinist